J&J Halts Sales of Morcellators for Uterine Fibroid Surgery

Share this content:
J&J Halts Sales of Morcellators for Uterine Fibroid Surgery
J&J Halts Sales of Morcellators for Uterine Fibroid Surgery

(HealthDay News) -- Morcellator sales have been halted due to concerns that use of the device in fibroid removal may worsen undetected uterine sarcoma, Johnson & Johnson said.

The company noted that while worldwide sales, distribution, and promotion of the device have been suspended, it will not be taken off the market, the Wall Street Journal reported.

RELATED: FDA Warns Against Morcellation for Uterine Fibroids

J&J took the action after the U.S. Food and Drug Administration warned doctors on April 17 that using a morcellator to remove uterine fibroids risked worsening uterine sarcoma. The FDA said that one in 350 women who undergo uterine fibroid removal procedures have undetected uterine sarcoma, WSJ reported.

RELATED: Excessive Uterine Leiomyosarcoma Dissemination Risk During Uterine Morcellation

An FDA advisory committee will meet this summer to more closely examine morcellator use during uterine fibroid surgery. In a letter to customers, J&J said it was awaiting input from the FDA and the medical community.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs